Approach to a Patient with Elevated Serum Alkaline Phosphatase
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Cholestasis develops either from a defect in bile synthesis, impairment in bile secretion, or obstruction to bile flow, and is characterized by an elevated serum alkaline phosphatase and gamma-glutamyltransferase disproportionate to elevation of aminotransferase enzymes. Key elements to the diagnostic workup include visualization of the biliary tree by cholangiography and evaluation of liver histology. The hope is that recent advances in understanding the genetic factors and immune mechanisms involved in the pathogenesis of cholestasis will lead to newer therapeutic interventions in the treatment of these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636 · cited 1×
“The bile acid transporters are subject to extensive regulation at both the transcriptional and posttranscriptional levels.(12) Nuclear receptors play an important role in bile acid metabolism and are activated by different compounds to”
BackgroundIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Racial Differences in Sarcoidosis Incidence: A 5-Year Study in a Health Maintenance Organization
Rybicki, B. A., Major, M., Popovich, J., Maliank, M. J., & lannuzzi, M. C. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009096 · Cited by 1,011 · cited 3×
“Sarcoidosis is amultisystemicdiseaseof unknownorigin characterizedby thepresence of noncaseating granulomata.113 Sarcoidosis primarily affects the lungs and lymph nodesbut can involve almost every organ, including the liver.114Hepatic sarcoid usually affects individuals between 20 and 40 years of age; AfricanAmericans…”
BackgroundInfluentialBile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999 · cited 1×
“by sodium taurocholate cotransporting polypeptide (NTCP; SLC10A1) and Na1-independent transport mediated by organic anion transporting proteins (OATPs; OATP2, SLC21A6).(2) NTCP is exclusively expressed in hepatocytes and is involved in the transport of both conjugated and unconjugated bile acids.”
BackgroundImmunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890 · cited 2×
“IgG4-SC is associated with autoimmune pancreatitis (AIP) in 80% to 90% of patients.(105)”
BackgroundCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393 · cited 1×
“An annual MRI/MRCP or ultrasound along with CA19-9 is recommended for screening for cholangiocarcinoma.(96) Patients with PSC also have increased prevalence of gallbladder cancer, colorectal cancer or dysplasia, and hepatocellular cancer.”
BackgroundA controlled trial of naloxone infusions for the pruritus of chronic cholestasis
Bergasa, N. V., Talbot, T. L., Alling, D. W., Schmitt, J. M., Walker, E. C., Baker, B. L., Korenman, J. C., Park, Y., Hoofnagle, J. H., & Jones, E. A. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90102-5 · Cited by 287 · cited 1×
“The main drawback for their use, however, is the potential for opioid withdrawal.(195) The role of UDCA was discussed earlier under specific chole-”
BackgroundTreatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267 · cited 1×
“Rifampin decreases hepatic uptake and facilitates renal elimination of bile acids.(190) The recommended dose is 300 to 600 mg/d.”
BackgroundPrince, M. I., Chetwynd, A., Craig, W. L., Metcalf, J. V., & James, O. F. W. (2004) · Gut · doi:10.1136/gut.2003.023937 · Cited by 261 · cited 1×
“Nearly 60% are asymptomatic at diagnosis and are incidentally detected to have an elevated serum AP level.(63) Fatigue and pruritus are common symptoms and may be present in 40% to 80% of patients, although these symptoms do not correlate with the severity of liver disease.”
BackgroundSclerosing cholangitis: a focus on secondary causes
Abdalian, R., & Heathcote, J. E. (2006) · Hepatology · doi:10.1002/hep.21405 · Cited by 230 · cited 1×
“bile duct injury from intraarterial chemotherapy, AIDS cholangiopathy, recurrent pyogenic cholangitis, and bile duct injury during surgery.(94) Patients with PSC are at risk for development of several malignancies.”
BackgroundFamilial primary biliary cirrhosis reassessed: a geographically-based population study
Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213
Quality of life before and after liver transplantation for cholestatic liver disease
Gross, C. R., Malinchoc, M., Kim, R. W., Evans, R. W., Wiesner, R. H., Petz, J. L., Crippin, J. S., Klintmalm, G. B., Levy, M. F., Ricci, P., et al. (1999) · Hepatology · doi:10.1002/hep.510290229 · Cited by 192 · cited 1×
“UDCA has not been shown to be useful, and fatigue may persist even after liver transplant, although its intensity may be reduced.(198,199) Central nervous system stimulants such as modafinil and low-dose amitriptyline may be beneficial in some patients.”
BackgroundBergquist, A., Montgomery, S. M., Bahmanyar, S., Olsson, R., Danielsson, Å., Lindgren, S., Prytz, H., Hultcrantz, R., Lööf, L., Sandberg–Gertzén, H., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.016 · Cited by 188
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
Hypercholesterolemia and Atherosclerosis in Primary Biliary Cirrhosis: What Is the Risk?
Crippin, J. S., Lindor, K. D., Jorgensen, R., Kottke, B. A., Harrison, J. M., Murtaugh, P. A., & Dickson, R. E. (1992) · Hepatology · doi:10.1002/hep.1840150518 · Cited by 149
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120
Guañabens, N., Parés, A., Ros, I., Alvarez, L., Pons, F., Caballería, L., Monegal, A., de Osaba, J. M. M., Roca, M., Peris, P., et al. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07639.x · Cited by 119 · cited 1×
“In a study comparing etidronate and alendronate, the latter was found to be more effective in increasing bone mass.(201)”
BackgroundFat-soluble vitamin levels in patients with primary biliary cirrhosis
Phillips, J. R., Angulo, P., Petterson, T., & Lindor, K. D. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04134.x · Cited by 118 · cited 1×
“Careful attention to prevent and treat these vitamin deficiencies plays an important role in the treatment of chronic cholestatic diseases.(33)”
BackgroundJONES, D. E. J., & NEWTON, J. L. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03223.x · Cited by 114 · cited 1×
“Central nervous system stimulants such as modafinil and low-dose amitriptyline may be beneficial in some patients.(200)”
BackgroundBiliary candida infections in primary sclerosing cholangitis
Kulaksiz, H., Rudolph, G., Kloeters-Plachky, P., Sauer, P., Geiss, H., & Stiehl, A. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.022 · Cited by 74
Berg, P. A., & Klein, R. (2008) · Digestive Diseases · doi:10.1159/000171347 · Cited by 57
An increased risk of urinary tract infection precedes development of primary biliary cirrhosis
Varyani, F. K., West, J., & Card, T. R. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-95 · Cited by 47 · cited 1×
“certain infections (Chlamydia pneumoniae, Escherichia coli, retrovirus, Novosphingobium aromaticivorans, lactobacilli) are thought to play a role in the pathogenesis of PBC through possibly either triggering an autoimmune reaction or causing a direct toxic effect.(60,61) Smoking is a possible risk factor for the devel…”
BackgroundParadoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis
Schaffner, F. (1969) · Gastroenterology · doi:10.1016/s0016-5085(19)33896-x · Cited by 33
Cited by
Small Molecule as Fluorescent Probes for Monitoring Intracellular Enzymatic Transformations
Singh, H., Tiwari, K., Tiwari, R., Pramanik, S. K., & Das, A. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00379 · Cited by 343
Sundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Metadata
- Authors
- Siddique, A., & Kowdley, K. V.
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 16
- Issue
- 2
- Pages
- 199-229
- ISSN
- 1089-3261 (ISSN-L)
- OpenAlex
- W2021974025
- Cited by
- 98
- References
- 27
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.